These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

574 related items for PubMed ID: 25677767

  • 1. Helix-constrained nociceptin peptides are potent agonists and antagonists of ORL-1 and nociception.
    Lohman RJ, Harrison RS, Ruiz-Gómez G, Hoang HN, Shepherd NE, Chow S, Hill TA, Madala PK, Fairlie DP.
    Vitam Horm; 2015; 97():1-55. PubMed ID: 25677767
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and biological activity of small peptides as NOP and opioid receptors' ligands: view on current developments.
    Naydenova E, Todorov P, Zamfirova R.
    Vitam Horm; 2015; 97():123-46. PubMed ID: 25677770
    [Abstract] [Full Text] [Related]

  • 3. Nociceptin, endogenous opioid peptide. Preface.
    Litwack G.
    Vitam Horm; 2015; 97():xv-xvi. PubMed ID: 25677779
    [No Abstract] [Full Text] [Related]

  • 4. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic.
    Thompson AA, Liu W, Chun E, Katritch V, Wu H, Vardy E, Huang XP, Trapella C, Guerrini R, Calo G, Roth BL, Cherezov V, Stevens RC.
    Nature; 2012 May 16; 485(7398):395-9. PubMed ID: 22596163
    [Abstract] [Full Text] [Related]

  • 5. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
    Witkin JM, Statnick MA, Rorick-Kehn LM, Pintar JE, Ansonoff M, Chen Y, Tucker RC, Ciccocioppo R.
    Pharmacol Ther; 2014 Mar 16; 141(3):283-99. PubMed ID: 24189487
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Nociceptin (ORL-1) and mu-opioid receptors mediate mitogen-activated protein kinase activation in CHO cells through a Gi-coupled signaling pathway: evidence for distinct mechanisms of agonist-mediated desensitization.
    Hawes BE, Fried S, Yao X, Weig B, Graziano MP.
    J Neurochem; 1998 Sep 16; 71(3):1024-33. PubMed ID: 9721727
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.
    Zaveri NT, Journigan VB, Polgar WE.
    ACS Chem Neurosci; 2015 Apr 15; 6(4):646-57. PubMed ID: 25635572
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors.
    Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, Kieffer BL, Takeshima H, Carroll FI, Maidment NT, Evans CJ.
    J Neurosci; 2003 Nov 12; 23(32):10331-7. PubMed ID: 14614092
    [Abstract] [Full Text] [Related]

  • 14. Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin.
    Sbrenna S, Marti M, Morari M, Calo' G, Guerrini R, Beani L, Bianchi C.
    Br J Pharmacol; 2000 May 12; 130(2):425-33. PubMed ID: 10807682
    [Abstract] [Full Text] [Related]

  • 15. Synergistic interaction between the agonism of cebranopadol at nociceptin/orphanin FQ and classical opioid receptors in the rat spinal nerve ligation model.
    Christoph T, Raffa R, De Vry J, Schröder W.
    Pharmacol Res Perspect; 2018 Dec 12; 6(6):e00444. PubMed ID: 30519474
    [Abstract] [Full Text] [Related]

  • 16. A selective small molecule NOP (ORL-1 receptor) partial agonist for the treatment of anxiety.
    Ross TM, Battista K, Bignan GC, Brenneman DE, Connolly PJ, Liu J, Middleton SA, Orsini M, Reitz AB, Rosenthal DI, Scott MK, Vaidya AH.
    Bioorg Med Chem Lett; 2015 Feb 01; 25(3):602-6. PubMed ID: 25556095
    [Abstract] [Full Text] [Related]

  • 17. Carboxyl terminal peptides derived from prepro-orphanin FQ/nociceptin (ppOFQ/N) are produced in the hypothalamus and possess analgesic bioactivities.
    Mathis JP, Rossi GC, Pellegrino MJ, Jimenez C, Pasternak GW, Allen RG.
    Brain Res; 2001 Mar 23; 895(1-2):89-94. PubMed ID: 11259764
    [Abstract] [Full Text] [Related]

  • 18. Bioinformatics and evolution of vertebrate nociceptin and opioid receptors.
    Stevens CW.
    Vitam Horm; 2015 Mar 23; 97():57-94. PubMed ID: 25677768
    [Abstract] [Full Text] [Related]

  • 19. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
    Sukhtankar DD, Zaveri NT, Husbands SM, Ko MC.
    J Pharmacol Exp Ther; 2013 Jul 23; 346(1):11-22. PubMed ID: 23652222
    [Abstract] [Full Text] [Related]

  • 20. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
    Tzschentke TM, Rutten K.
    Neuropharmacology; 2018 Feb 23; 129():100-108. PubMed ID: 29155273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.